Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Dipyridamole in Asasantin ER Formulations
NCT02273557Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2003
- Primary completion
- Feb 2003
- Modality
- Small Molecules, Drug Delivery Systems
01
Overview
Phase 1, randomised, open-label trial of dipyridamole + aspirin in ischemic stroke (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Urinary excretion of dipyridamole at day 3. Started Jan 2003; status: completed.
02
Drugs
dipyridamole + aspirin
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT02273557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02273557.